R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation

William C. Nichols, Diane K. Marek, Michael W. Pauciulo, Nathan Pankratz, Cheryl A. Halter, Alice Rudolph, Clifford W. Shults, Joanne Wojcieszek, Tatiana Foroud, C. Shults, F. Marshall, D. Oakes, A. Rudolph, A. Shinaman, K. Marder, P. M. Conneally, T. Foroud, C. Halter, K. Lyons, E. SiemersS. Factor, D. Higgins, S. Evans, H. Shill, M. Stacy, J. Danielson, L. Marlor, K. Williamson, J. Jankovic, C. Hunter, D. Simon, P. Ryan, L. Scollins, R. Saunders-Pullman, K. Boyar, C. Costan-Toth, E. Ohmann, L. Sudarsky, C. Joubert, J. Friedman, K. Chou, H. Fernandez, M. Lannon, N. Galvez-Jimenez, A. Podichetty, P. Lewitt, M. DeAngelis, C. O'Brien, L. Seeberger, C. Dingmann, D. Judd, K. Marder, J. Fraser, J. Harris, J. Bertoni, C. Peterson, S. Chouinard, M. Panisset, J. Hall, H. Poiffaut, V. Calabrese, P. Roberge, J. Wojcieszek, J. Belden, C. Halter, D. Jennings, K. Marek, S. Mendick, S. Reich, B. Dunlop, M. Jog, C. Horn, J. Rao, M. Cook, R. Uitti, M. Turk, T. Ajax, J. Mannetter, M. Panisset, J. Hall, K. Sethi, J. Carpenter, K. Ligon, S. Narayan, L. Woodward, K. Blindauer, J. Petit, L. Elmer, E. Aiken, K. Davis, C. Schell, S. Wilson, M. Velickovic, W. Koller, S. Phipps, A. Feigin, M. Gordon, J. Hamann, E. Licari, M. Marotta-Kollarus, B. Shannon, R. Winnick, T. Simuni, A. Kaczmarek, K. Williams, M. Wolff, M. Fernandez, J. Hubble, S. Kostyk, A. Campbell, C. Reider, R. Camicioli, J. Carter, P. Andrews, S. Morehouse, C. Stone, T. Mendis, D. Grimes, P. Gray, K. Haas, J. Sutton, B. Hutchinson, J. Young, A. Rajput, A. Rajput, L. Klassen, T. Shirley, B. Manyam, P. Simpson, J. Whetteckey, B. Wulbrecht, D. Truong, M. Pathak, N. Luong, T. Tra, A. Tran, J. Vo, A. Lang, G. Kleiner-Fisman, A. Nieves, J. So, G. Podskalny, L. Giffin, P. Atchison, C. Allen, W. Martin, M. Wieler, O. Suchowersky, M. Klimek, N. Hermanowicz, S. Niswonger, C. Shults, D. Fontaine, M. Aminoff, C. Christine, M. Diminno, J. Hevezi, A. Dalvi, U. Kang, J. Richman, S. Uy, J. Young, A. Dalvi, A. Sahay, D. Schwieterman, M. Leehey, S. Culver, T. Derian, T. Demarcaida, S. Belber, R. Rodnitzky, J. Dobson, R. Pahwa, K. Lyons, T. Gales, S. Thomas, L. Shulman, W. Weiner, K. Dustin, C. Singer, W. Koller, K. Lyons, W. Weiner, L. Zelaya, P. Tuite, V. Hagen, S. Rolandelli, R. Schacherer, P. Gordon, J. Werner, C. Serrano, S. Roque, R. Kurlan, D. Berry, I. Gardiner, R. Hauser, J. Sanchez-Ramos, T. Zesiewicz, H. Delgado, K. Price, P. Rodriguez, R. Pfeiffer, L. Davis, B. Pfeiffer, R. Dewey, B. Hayward, M. Meacham, F. Walker, V. Hunt, B. Racette, L. Good, M. Rundle, A. Watts, A. Wang, T. Ross, S. Bennett, D. Kamp, E. Julian-Baros

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Mutations in LRRK2 were first reported as causing Parkinson's disease (PD) in late 2004. Since then, approximately a dozen LRRK2 substitutions have been identified that are believed to be pathogenic mutations. The substitution of adenine for guanine at nucleotide 4541 (4541G>A) in LRRK2 was recently reported. This substitution resulted in the replacement of an arginine at position 1514 with a glutamine (R1514Q). Although this substitution was not found in a large cohort of controls, its pathogenicity could not be verified. We have now genotyped the R1514Q substitution in a sample of 954 PD patients from 429 multiplex PD families. This substitution was identified in 1.8% of the PD patients; however, the majority of the PD sibships segregating this substitution were discordant for this putative mutation. In addition, the R1514Q substitution was detected in 1.4% of neurologically evaluated, control individuals. These data suggest that the R1514Q variant is not a pathogenic LRRK2 mutation. We believe it is imperative that the causative nature of any newly identified genetic variant be determined before it is included in any panel for diagnostic testing.

Original languageEnglish (US)
Pages (from-to)254-256
Number of pages3
JournalMovement Disorders
Volume22
Issue number2
DOIs
StatePublished - Jan 15 2007

Keywords

  • Genetics
  • LRRK2
  • Mutation
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation'. Together they form a unique fingerprint.

Cite this